PRODUCTS & SERVICES
Zuzana Caputova, the president of the Slovak Republic, and her team visited MultiplexDX.
As one of the leading biotech companies in our region, we had the privilege to present Ms. Caputova our breakthrough diagnostic for breast cancer. Our test is already being used prospectively for the first patients with breast cancer in Slovakia.
Ms. President enthralled us with her incredible energy and profound interest in our team and the tech behind the R&D. Despite her busy schedule she managed to meet and talk with the whole team.
MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).
MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.